<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243658</url>
  </required_header>
  <id_info>
    <org_study_id>OX02</org_study_id>
    <nct_id>NCT01243658</nct_id>
  </id_info>
  <brief_title>&quot;The Effects of Oxytocin on Patients With Borderline Personality Disorder&quot;</brief_title>
  <official_title>&quot;The Effects of Oxytocin on Patients With Borderline Personality Disorder&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Markus Heinrichs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCT. Two substudies (clinical and experimental). Main objective of the trial is to examine if
      oxytocin, compared to placebo shows any additional effect on the therapy achievements
      (outcome) of patients with borderline personality disorder, who receive an in-patient
      standard psychotherapy (Dialectical-behavioral-therapy, Marsha Linehan (2006)).

      Secondary objectives :

      Investigate if oxytocin compared to placebo enhances social trust and emotion recognition in
      patients with borderline personality disorder. Comparison of the effects of Oxytocin on
      patients with BPD and major depression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPD Symptoms</measure>
    <time_frame>BPD Symptoms</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Effects of Oxytocin on Borderline Personality Disorder</condition>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin</description>
    <arm_group_label>Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: Both, male and female

          -  Minimum Age: 18 Years

          -  Maximum Age: 50 Years

          -  Borderline personality disorder or major depression (clinical control group)

          -  Mini Mental Status Test &gt; 27 (capacity to consent)

        Exclusion Criteria:

          -  chronic or acute somatic health problems

          -  Schizophrenia

          -  Bipolar affective disorder

          -  pregnancy

          -  breast feeding

          -  neurological disorder

          -  allergy to antidegradants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Heinrichs, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Institut f체r Psychologie der Univerist채t Freiburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franny B Spengler, Dr.</last_name>
    <phone>0049-761-20397742</phone>
    <email>franny.spengler@psychologie.uni-freiburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albert-Ludwigs-Universit채t-Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-W체rtemberg</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franny B Spengler, Dr.</last_name>
      <phone>0049-761-20397742</phone>
      <email>franny.spengler@psychologie.uni-freiburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Markus Heinrichs</investigator_full_name>
    <investigator_title>Prof. Dr. Markus Heinrichs</investigator_title>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>BPD</keyword>
  <keyword>Borderline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

